Compare Automatic Data Processing Inc (ADP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Automatic Data Processing Inc vs Summit Therapeutics Inc — how do they compare? Automatic Data Processing Inc trades at $242.18 (market cap $98.17B), while Summit Therapeutics Inc trades at $15.5 (market cap $12.32B). The key difference: Automatic Data Processing Inc is far larger — about 8× Summit Therapeutics Inc's market cap, and Automatic Data Processing Inc pays a 2.77% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ADP | SMMT | |
|---|---|---|
Market Cap | $98.17B | $12.32B |
Sector | Industrials | Health |
52-Week High | $310.94 | $29.32 |
52-Week Low | $188.79 | $13.05 |
Enterprise Value | $99.24B | $11.74B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $245.60, up 1.37% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats in recent quarters. Revenue grew to $20.56 billion in 2025, with a net income margin of 20.12%. Analyst sentiment is mixed, with a consensus hold rating but a technical outlook suggesting strength. The company maintains strong profitability metrics and recently announced a dividend payment.
Outlook remains stable with projected revenue growth to $21.6 billion in 2026. Risks include competitive pressures and economic sensitivity. Opportunities lie in AI integration and margin expansion. The stock offers value through dividends and steady performance, though valuation multiples are elevated relative to historical averages.
Summit Therapeutics (SMMT) trades at $15.93, up 3.31% today, with a bullish technical signal despite mixed moving averages and overbought RSI readings. The company reported a net loss of -$1.08B in 2025 and negative ROE/ROA, but recent Phase III trial success for ivonescimab in lung cancer has driven optimism. Cash flow remains volatile, with 2025 net cash flow positive at $120.4M but turning negative in 2026 projections.
Outlook hinges on ivonescimab's regulatory approval and commercial potential, with a consensus price target of $22.93 implying 44% upside. High volatility and binary clinical outcomes pose significant risks, but strong analyst buy ratings (66.7%) reflect confidence in the drug's prospects. Investors face substantial dilution risk from a proposed $500M stock offering announced June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
